FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

The agency’s decision is based on results from the phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with solid tumors.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.

Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.